Loading ...

Stock Quote ab3a

ab3a Stock Price Today

ab3a Price History

ab3a Stock Price History

ab3a History

Last Price ab3a

Close Price ab3a

Day Change ab3a

After Hours Quote ab3a

Open Price ab3a

Day Range ab3a

Year Range ab3a

Projected Yield ab3a

Market Cap ab3a

Stock Volume ab3a

Average Volume ab3a

Forward Price ab3a

PE for ab3a

PB for ab3a

PS for ab3a

PCF for ab3a

price earnings ratio ab3a

price to book ratio ab3a

price to sales ratio ab3a

price to cash flow ratio ab3a

Stock Quote Sarepta Therapeutics Inc

Sarepta Therapeutics Inc Stock Price today

Sarepta Therapeutics Inc Price history

Sarepta Therapeutics Inc Stock Price history

Sarepta Therapeutics Inc history

Last Price Sarepta Therapeutics Inc

Close Price Sarepta Therapeutics Inc

Day Change Sarepta Therapeutics Inc

After Hours Quote for Sarepta Therapeutics Inc

Open Price Sarepta Therapeutics Inc

Day Range Sarepta Therapeutics Inc

Year Range Sarepta Therapeutics Inc

Projected Yield Sarepta Therapeutics Inc

Market Cap Sarepta Therapeutics Inc

Stock Volume Sarepta Therapeutics Inc

Average Volume Sarepta Therapeutics Inc

Forward Price Sarepta Therapeutics Inc

pe Sarepta Therapeutics Inc

pb Sarepta Therapeutics Inc

ps Sarepta Therapeutics Inc

pcf Sarepta Therapeutics Inc

price earnings ratio Sarepta Therapeutics Inc

price to book ratio Sarepta Therapeutics Inc

price to sales ratio Sarepta Therapeutics Inc

price to cash flow ratio Sarepta Therapeutics Inc

What Does This Company Do?
Sarepta Therapeutics Inc discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include eteplirsen, AVI-6002, AVI-6003, and AVI-7100.
Sector
Healthcare
Industry
Biotechnology
Stock Type
Distressed
Employees
146
Stock Style
Small Growth

Key Stats  AB3A More...

Key Stats AB3A

S&P 500 index data: S&P 500 Copyright ©

All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .



Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Sponsor Center

Analysis  ab3a - Sarepta Therapeutics Inc More...

Free Issue - Morningstar's Dividend Newsletter
More...

An investment is only as good as the cash it returns directly to your pockets. That's why Morningstar DividendInvestor's buy and sell recommendations are driven entirely by dividends. Our total-return strategy gives you carefully selected, picks that combine current income and income growth to generate large, reliable and growing cash returns. Click to try!

News  ab3a - Sarepta Therapeutics Inc More...

Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate (2014/2/10)
Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments (2014/2/27)
Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer (2014/1/9)
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy (2014/1/15)
Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy (2014/2/5)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT (2014/3/7)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT) (2014/3/22)
Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc., (2014/1/30)
INVESTOR ALERT: Federman & Sherwood Investigates Sarepta Therapeutics, Inc. for Possible Securities Laws Violations (2013/11/13)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT (2014/3/4)

More reports ab3a - Sarepta Therapeutics IncMore...

Click above to view more mutual fund data and stats for ab3a - Sarepta Therapeutics Inc.

  • Performance
  • Asset Allocation
  • Dividend and Capital Gains Distribution
  • News, Alerts and Opinions
  • Video reports
  • Management
  • Filings

Ownership   AB3A More ...

Ownership AB3A

Columbia Acorn Z
Fidelity® Select Biotechnology Portfolio
Lord Abbett Fundamental Equity C
Vanguard Small Cap Index
Vanguard Total Stock Mkt Idx
Stock Price Quote: ab3a Sarepta Therapeutics Inc - XFRA - Morningstar
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry

Previous: 532163 - Saregama India Ltd.  |  Next: srpt - Sarepta Therapeutics Inc